Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

Summary

This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.

Timeline

Start

2016-01-26

Primary completion

2019-12-01

Completion

2019-12-01

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

Indications